Key clinical point: Despite no significant improvement in pain-free status, high-dose zolmitriptan nasal spray (ZNS) provided clinically relevant improvements with a favorable safety profile in the acute treatment of migraine in patients aged 6-11 years.

Major finding: At 2 hours postdose, high-dose ZNS vs placebo led to a numerically higher proportion of patients achieving pain-free status (odds ratio [OR] 1.51; 95% CI 0.96-2.38) and a significantly higher proportion of patients reporting a headache response (OR 1.75; P = .009). No serious treatment-emergent adverse events were reported.

Study details: This was a phase 3 crossover trial with an open-label extension including 186 patients aged 6-11 years with migraine with or without aura who were randomly assigned to receive ZNS (patients <50 kg: 2.5 or 1 mg; patients ≥50 kg: 5 or 2.5 mg) or placebo.

Disclosures: This trial was funded by AstraZeneca and conducted by Amneal Pharmaceuticals LLC, which also supported the study’s publication. Two authors declared being employees of Amneal or a company contracted by Amneal. Two authors reported ties with various other sources.

Source: Yonker ME et al. A multicenter, randomized, double-blind, placebo-controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11 years, with an open-label extension. Headache. 2022;62(9):1207-1217 (Oct 26). Doi: 10.1111/head.14391

Key clinical point: Despite no significant improvement in pain-free status, high-dose zolmitriptan nasal spray (ZNS) provided clinically relevant improvements with a favorable safety profile in the acute treatment of migraine in patients aged 6-11 years.

Major finding: At 2 hours postdose, high-dose ZNS vs placebo led to a numerically higher proportion of patients achieving pain-free status (odds ratio [OR] 1.51; 95% CI 0.96-2.38) and a significantly higher proportion of patients reporting a headache response (OR 1.75; P = .009). No serious treatment-emergent adverse events were reported.

Study details: This was a phase 3 crossover trial with an open-label extension including 186 patients aged 6-11 years with migraine with or without aura who were randomly assigned to receive ZNS (patients <50 kg: 2.5 or 1 mg; patients ≥50 kg: 5 or 2.5 mg) or placebo.

Disclosures: This trial was funded by AstraZeneca and conducted by Amneal Pharmaceuticals LLC, which also supported the study’s publication. Two authors declared being employees of Amneal or a company contracted by Amneal. Two authors reported ties with various other sources.

Source: Yonker ME et al. A multicenter, randomized, double-blind, placebo-controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11 years, with an open-label extension. Headache. 2022;62(9):1207-1217 (Oct 26). Doi: 10.1111/head.14391

Key clinical point: Despite no significant improvement in pain-free status, high-dose zolmitriptan nasal spray (ZNS) provided clinically relevant improvements with a favorable safety profile in the acute treatment of migraine in patients aged 6-11 years.

Major finding: At 2 hours postdose, high-dose ZNS vs placebo led to a numerically higher proportion of patients achieving pain-free status (odds ratio [OR] 1.51; 95% CI 0.96-2.38) and a significantly higher proportion of patients reporting a headache response (OR 1.75; P = .009). No serious treatment-emergent adverse events were reported.

Study details: This was a phase 3 crossover trial with an open-label extension including 186 patients aged 6-11 years with migraine with or without aura who were randomly assigned to receive ZNS (patients <50 kg: 2.5 or 1 mg; patients ≥50 kg: 5 or 2.5 mg) or placebo.

Disclosures: This trial was funded by AstraZeneca and conducted by Amneal Pharmaceuticals LLC, which also supported the study’s publication. Two authors declared being employees of Amneal or a company contracted by Amneal. Two authors reported ties with various other sources.

Source: Yonker ME et al. A multicenter, randomized, double-blind, placebo-controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11 years, with an open-label extension. Headache. 2022;62(9):1207-1217 (Oct 26). Doi: 10.1111/head.14391

Key clinical point: A single dose of zavegepant nasal spray (20 or 10 mg) was effective for the acute treatment of migraine with a favorable safety profile.

Major finding: At 2 hours, a significantly higher proportion of patients treated with 20 mg or 10 mg zavegepant vs placebo reported freedom from pain (23.1% and 22.5% vs 15.5%; P = .0055 and .0113, respectively) and most bothersome symptoms (42.5% and 41.9% vs 33.7%; P = .0094 and .0155, respectively), with adverse events being mostly mild or moderate and no indications for hepatotoxicity.

Study details: This phase 2/3 trial included 1673 patients with migraine with or without aura who were randomly assigned to receive zavegepant (5, 10, 20 mg) or placebo to treat a single migraine attack of moderate-to-severe pain intensity.

Disclosures: This study was funded by Biohaven Pharmaceuticals, Inc. Seven authors declared being employees and holding stock or stock options in Biohaven Pharmaceuticals. RB Lipton declared holding stock options in Biohaven Pharmaceuticals and Manistee and reported ties with various other sources.

Source: Croop R et al. Zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache. 2022;62(9):1153-1163 (Oct 14). Doi: 10.1111/head.14389

Key clinical point: A single dose of zavegepant nasal spray (20 or 10 mg) was effective for the acute treatment of migraine with a favorable safety profile.

Major finding: At 2 hours, a significantly higher proportion of patients treated with 20 mg or 10 mg zavegepant vs placebo reported freedom from pain (23.1% and 22.5% vs 15.5%; P = .0055 and .0113, respectively) and most bothersome symptoms (42.5% and 41.9% vs 33.7%; P = .0094 and .0155, respectively), with adverse events being mostly mild or moderate and no indications for hepatotoxicity.

Study details: This phase 2/3 trial included 1673 patients with migraine with or without aura who were randomly assigned to receive zavegepant (5, 10, 20 mg) or placebo to treat a single migraine attack of moderate-to-severe pain intensity.

Disclosures: This study was funded by Biohaven Pharmaceuticals, Inc. Seven authors declared being employees and holding stock or stock options in Biohaven Pharmaceuticals. RB Lipton declared holding stock options in Biohaven Pharmaceuticals and Manistee and reported ties with various other sources.

Source: Croop R et al. Zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache. 2022;62(9):1153-1163 (Oct 14). Doi: 10.1111/head.14389

Key clinical point: A single dose of zavegepant nasal spray (20 or 10 mg) was effective for the acute treatment of migraine with a favorable safety profile.

Major finding: At 2 hours, a significantly higher proportion of patients treated with 20 mg or 10 mg zavegepant vs placebo reported freedom from pain (23.1% and 22.5% vs 15.5%; P = .0055 and .0113, respectively) and most bothersome symptoms (42.5% and 41.9% vs 33.7%; P = .0094 and .0155, respectively), with adverse events being mostly mild or moderate and no indications for hepatotoxicity.

Study details: This phase 2/3 trial included 1673 patients with migraine with or without aura who were randomly assigned to receive zavegepant (5, 10, 20 mg) or placebo to treat a single migraine attack of moderate-to-severe pain intensity.

Disclosures: This study was funded by Biohaven Pharmaceuticals, Inc. Seven authors declared being employees and holding stock or stock options in Biohaven Pharmaceuticals. RB Lipton declared holding stock options in Biohaven Pharmaceuticals and Manistee and reported ties with various other sources.

Source: Croop R et al. Zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache. 2022;62(9):1153-1163 (Oct 14). Doi: 10.1111/head.14389

Key clinical point: The odds of anxiety and depression disorders were significantly higher in children and adolescents with migraine compared with control individuals, highlighting the need to routinely screen children and adolescents with migraine for anxiety and depression.

Major finding: Children and adolescents with migraine vs control individuals were at a higher risk for anxiety disorders (odds ratio [OR] 1.93; 95% CI 1.49-2.50), depressive disorders (OR 2.01; 95% CI 1.46-2.78), and mixed internalizing (anxiety and depressive) disorders (OR 4.69; 95% CI 3.08-7.14).

Study details: This was a systematic review of 80 observational studies, of which 51 involving children and adolescents with migraine and control individuals were included in the meta-analysis.

Disclosures: This study was supported by the Alberta Children’s Hospital Research Institute (ACHRI) and Cumming School of Medicine, Canada. SL Orr reported receiving royalties for book publication, grant funding from the Canadian Health Research and ACHRI, and serving on the editorial boards of journals and the American Migraine Foundation.

Source: Falla K et al. Anxiety and depressive symptoms and disorders in children and adolescents with migraine: A systematic review and meta-analysis. JAMA Pediatr. 2022 (Oct 31). Doi: 10.1001/jamapediatrics.2022.3940

Key clinical point: The odds of anxiety and depression disorders were significantly higher in children and adolescents with migraine compared with control individuals, highlighting the need to routinely screen children and adolescents with migraine for anxiety and depression.

Major finding: Children and adolescents with migraine vs control individuals were at a higher risk for anxiety disorders (odds ratio [OR] 1.93; 95% CI 1.49-2.50), depressive disorders (OR 2.01; 95% CI 1.46-2.78), and mixed internalizing (anxiety and depressive) disorders (OR 4.69; 95% CI 3.08-7.14).

Study details: This was a systematic review of 80 observational studies, of which 51 involving children and adolescents with migraine and control individuals were included in the meta-analysis.

Disclosures: This study was supported by the Alberta Children’s Hospital Research Institute (ACHRI) and Cumming School of Medicine, Canada. SL Orr reported receiving royalties for book publication, grant funding from the Canadian Health Research and ACHRI, and serving on the editorial boards of journals and the American Migraine Foundation.

Source: Falla K et al. Anxiety and depressive symptoms and disorders in children and adolescents with migraine: A systematic review and meta-analysis. JAMA Pediatr. 2022 (Oct 31). Doi: 10.1001/jamapediatrics.2022.3940

Key clinical point: The odds of anxiety and depression disorders were significantly higher in children and adolescents with migraine compared with control individuals, highlighting the need to routinely screen children and adolescents with migraine for anxiety and depression.

Major finding: Children and adolescents with migraine vs control individuals were at a higher risk for anxiety disorders (odds ratio [OR] 1.93; 95% CI 1.49-2.50), depressive disorders (OR 2.01; 95% CI 1.46-2.78), and mixed internalizing (anxiety and depressive) disorders (OR 4.69; 95% CI 3.08-7.14).

Study details: This was a systematic review of 80 observational studies, of which 51 involving children and adolescents with migraine and control individuals were included in the meta-analysis.

Disclosures: This study was supported by the Alberta Children’s Hospital Research Institute (ACHRI) and Cumming School of Medicine, Canada. SL Orr reported receiving royalties for book publication, grant funding from the Canadian Health Research and ACHRI, and serving on the editorial boards of journals and the American Migraine Foundation.

Source: Falla K et al. Anxiety and depressive symptoms and disorders in children and adolescents with migraine: A systematic review and meta-analysis. JAMA Pediatr. 2022 (Oct 31). Doi: 10.1001/jamapediatrics.2022.3940

Key clinical point: The odds of anxiety and depression disorders were significantly higher in children and adolescents with migraine compared with control individuals, highlighting the need to routinely screen children and adolescents with migraine for anxiety and depression.

Major finding: Children and adolescents with migraine vs control individuals were at a higher risk for anxiety disorders (odds ratio [OR] 1.93; 95% CI 1.49-2.50), depressive disorders (OR 2.01; 95% CI 1.46-2.78), and mixed internalizing (anxiety and depressive) disorders (OR 4.69; 95% CI 3.08-7.14).

Study details: This was a systematic review of 80 observational studies, of which 51 involving children and adolescents with migraine and control individuals were included in the meta-analysis.

Disclosures: This study was supported by the Alberta Children’s Hospital Research Institute (ACHRI) and Cumming School of Medicine, Canada. SL Orr reported receiving royalties for book publication, grant funding from the Canadian Health Research and ACHRI, and serving on the editorial boards of journals and the American Migraine Foundation.

Source: Falla K et al. Anxiety and depressive symptoms and disorders in children and adolescents with migraine: A systematic review and meta-analysis. JAMA Pediatr. 2022 (Oct 31). Doi: 10.1001/jamapediatrics.2022.3940

Key clinical point: The odds of anxiety and depression disorders were significantly higher in children and adolescents with migraine compared with control individuals, highlighting the need to routinely screen children and adolescents with migraine for anxiety and depression.

Major finding: Children and adolescents with migraine vs control individuals were at a higher risk for anxiety disorders (odds ratio [OR] 1.93; 95% CI 1.49-2.50), depressive disorders (OR 2.01; 95% CI 1.46-2.78), and mixed internalizing (anxiety and depressive) disorders (OR 4.69; 95% CI 3.08-7.14).

Study details: This was a systematic review of 80 observational studies, of which 51 involving children and adolescents with migraine and control individuals were included in the meta-analysis.

Disclosures: This study was supported by the Alberta Children’s Hospital Research Institute (ACHRI) and Cumming School of Medicine, Canada. SL Orr reported receiving royalties for book publication, grant funding from the Canadian Health Research and ACHRI, and serving on the editorial boards of journals and the American Migraine Foundation.

Source: Falla K et al. Anxiety and depressive symptoms and disorders in children and adolescents with migraine: A systematic review and meta-analysis. JAMA Pediatr. 2022 (Oct 31). Doi: 10.1001/jamapediatrics.2022.3940

Key clinical point: The odds of anxiety and depression disorders were significantly higher in children and adolescents with migraine compared with control individuals, highlighting the need to routinely screen children and adolescents with migraine for anxiety and depression.

Major finding: Children and adolescents with migraine vs control individuals were at a higher risk for anxiety disorders (odds ratio [OR] 1.93; 95% CI 1.49-2.50), depressive disorders (OR 2.01; 95% CI 1.46-2.78), and mixed internalizing (anxiety and depressive) disorders (OR 4.69; 95% CI 3.08-7.14).

Study details: This was a systematic review of 80 observational studies, of which 51 involving children and adolescents with migraine and control individuals were included in the meta-analysis.

Disclosures: This study was supported by the Alberta Children’s Hospital Research Institute (ACHRI) and Cumming School of Medicine, Canada. SL Orr reported receiving royalties for book publication, grant funding from the Canadian Health Research and ACHRI, and serving on the editorial boards of journals and the American Migraine Foundation.

Source: Falla K et al. Anxiety and depressive symptoms and disorders in children and adolescents with migraine: A systematic review and meta-analysis. JAMA Pediatr. 2022 (Oct 31). Doi: 10.1001/jamapediatrics.2022.3940

Key clinical point: Proton pump inhibitor (PPI) use is significantly associated with an increased risk for gastric cancer.

Major finding: PPI users vs nonusers were significantly more likely to develop gastric cancer (odds ratio 1.75; 95% CI 1.28-2.40).

Study details: This study meta-analyzed 16 observational studies (cohort and case-control studies; n = 2,936,935) that evaluated the association between PPI use and the risk for gastric cancer.

Disclosures: This study was sponsored by grants from the Taipei Tzu Chi Hospital and Buddhist Tzu Chi Medical Foundation, Taiwan. The authors declared no conflicts of interest.

Source: Peng TR et al. Association between proton-pump inhibitors and the risk of gastric cancer: A systematic review and meta-analysis. Int J Clin Oncol. 2022 (Oct 12). Doi: 10.1007/s10147-022-02253-2

Key clinical point: Proton pump inhibitor (PPI) use is significantly associated with an increased risk for gastric cancer.

Major finding: PPI users vs nonusers were significantly more likely to develop gastric cancer (odds ratio 1.75; 95% CI 1.28-2.40).

Study details: This study meta-analyzed 16 observational studies (cohort and case-control studies; n = 2,936,935) that evaluated the association between PPI use and the risk for gastric cancer.

Disclosures: This study was sponsored by grants from the Taipei Tzu Chi Hospital and Buddhist Tzu Chi Medical Foundation, Taiwan. The authors declared no conflicts of interest.

Source: Peng TR et al. Association between proton-pump inhibitors and the risk of gastric cancer: A systematic review and meta-analysis. Int J Clin Oncol. 2022 (Oct 12). Doi: 10.1007/s10147-022-02253-2

Key clinical point: Proton pump inhibitor (PPI) use is significantly associated with an increased risk for gastric cancer.

Major finding: PPI users vs nonusers were significantly more likely to develop gastric cancer (odds ratio 1.75; 95% CI 1.28-2.40).

Study details: This study meta-analyzed 16 observational studies (cohort and case-control studies; n = 2,936,935) that evaluated the association between PPI use and the risk for gastric cancer.

Disclosures: This study was sponsored by grants from the Taipei Tzu Chi Hospital and Buddhist Tzu Chi Medical Foundation, Taiwan. The authors declared no conflicts of interest.

Source: Peng TR et al. Association between proton-pump inhibitors and the risk of gastric cancer: A systematic review and meta-analysis. Int J Clin Oncol. 2022 (Oct 12). Doi: 10.1007/s10147-022-02253-2

Key clinical point: The occurrence of gastric cancer is highest in patients with SMAD4-associated juvenile polyposis syndrome (JPS) and is not reported in those without identifiable pathogenic germline variants (PGV).

Major finding: Gastric cancer occurred in 10.1% (95% CI 3.2%-16.8%) of patients with SMAD4 PGV and in only 1 patient with BMPR1A PGV. It was not reported in patients without an identifiable PGV.

Study details: This was a meta-analysis of 11 retrospective studies including 637 patients with JPS, of which 272 had a SMAD4 PGV, 181 had a BMPR1A PGV, 106 had no identifiable PGV, and 78 had an unknown PGV status.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Singh AD et al. Occurrence of gastric cancer in patients with juvenile polyposis syndrome: A systematic review and meta-analysis. Gastrointest Endosc. 2022 (Oct 17). Doi: 10.1016/j.gie.2022.10.026

Key clinical point: The occurrence of gastric cancer is highest in patients with SMAD4-associated juvenile polyposis syndrome (JPS) and is not reported in those without identifiable pathogenic germline variants (PGV).

Major finding: Gastric cancer occurred in 10.1% (95% CI 3.2%-16.8%) of patients with SMAD4 PGV and in only 1 patient with BMPR1A PGV. It was not reported in patients without an identifiable PGV.

Study details: This was a meta-analysis of 11 retrospective studies including 637 patients with JPS, of which 272 had a SMAD4 PGV, 181 had a BMPR1A PGV, 106 had no identifiable PGV, and 78 had an unknown PGV status.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Singh AD et al. Occurrence of gastric cancer in patients with juvenile polyposis syndrome: A systematic review and meta-analysis. Gastrointest Endosc. 2022 (Oct 17). Doi: 10.1016/j.gie.2022.10.026

Key clinical point: The occurrence of gastric cancer is highest in patients with SMAD4-associated juvenile polyposis syndrome (JPS) and is not reported in those without identifiable pathogenic germline variants (PGV).

Major finding: Gastric cancer occurred in 10.1% (95% CI 3.2%-16.8%) of patients with SMAD4 PGV and in only 1 patient with BMPR1A PGV. It was not reported in patients without an identifiable PGV.

Study details: This was a meta-analysis of 11 retrospective studies including 637 patients with JPS, of which 272 had a SMAD4 PGV, 181 had a BMPR1A PGV, 106 had no identifiable PGV, and 78 had an unknown PGV status.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Singh AD et al. Occurrence of gastric cancer in patients with juvenile polyposis syndrome: A systematic review and meta-analysis. Gastrointest Endosc. 2022 (Oct 17). Doi: 10.1016/j.gie.2022.10.026

Key clinical point: Gastric transcatheter chemoembolization (GTC) is a safe and effective alternative treatment method for advanced gastric cancer with obstruction.

Major finding: All patients achieved successful selection of tumor-feeding blood vessels and injection of chemotherapeutics and embolic agents, while 22 achieved a gastric outlet obstruction scoring system (GOOSS) score of ≥2. The median time of GTC was 83 minutes, and the median time of hospitalization after GTC was 3 days. One patient experienced abdominal pain during and after GTC. The pre- and post-intervention GOOSS scores were 1 and 2, respectively (P = .000).

Study details: This retrospective study included 42 patients with advanced gastric cancer complicated with obstruction who underwent GTC.

Disclosures: This study was supported by the Chongqing Science and Health Joint Project, China. The authors declared no conflicts of interest.

Source: Peng D et al. Gastric transcatheter chemoembolization can resolve advanced gastric cancer presenting with obstruction. Front Surg. 2022;9:1004064 (Oct 20). Doi: 10.3389/fsurg.2022.1004064

Key clinical point: Gastric transcatheter chemoembolization (GTC) is a safe and effective alternative treatment method for advanced gastric cancer with obstruction.

Major finding: All patients achieved successful selection of tumor-feeding blood vessels and injection of chemotherapeutics and embolic agents, while 22 achieved a gastric outlet obstruction scoring system (GOOSS) score of ≥2. The median time of GTC was 83 minutes, and the median time of hospitalization after GTC was 3 days. One patient experienced abdominal pain during and after GTC. The pre- and post-intervention GOOSS scores were 1 and 2, respectively (P = .000).

Study details: This retrospective study included 42 patients with advanced gastric cancer complicated with obstruction who underwent GTC.

Disclosures: This study was supported by the Chongqing Science and Health Joint Project, China. The authors declared no conflicts of interest.

Source: Peng D et al. Gastric transcatheter chemoembolization can resolve advanced gastric cancer presenting with obstruction. Front Surg. 2022;9:1004064 (Oct 20). Doi: 10.3389/fsurg.2022.1004064

Key clinical point: Gastric transcatheter chemoembolization (GTC) is a safe and effective alternative treatment method for advanced gastric cancer with obstruction.

Major finding: All patients achieved successful selection of tumor-feeding blood vessels and injection of chemotherapeutics and embolic agents, while 22 achieved a gastric outlet obstruction scoring system (GOOSS) score of ≥2. The median time of GTC was 83 minutes, and the median time of hospitalization after GTC was 3 days. One patient experienced abdominal pain during and after GTC. The pre- and post-intervention GOOSS scores were 1 and 2, respectively (P = .000).

Study details: This retrospective study included 42 patients with advanced gastric cancer complicated with obstruction who underwent GTC.

Disclosures: This study was supported by the Chongqing Science and Health Joint Project, China. The authors declared no conflicts of interest.

Source: Peng D et al. Gastric transcatheter chemoembolization can resolve advanced gastric cancer presenting with obstruction. Front Surg. 2022;9:1004064 (Oct 20). Doi: 10.3389/fsurg.2022.1004064

Key clinical point: The presence of sarcopenic obesity (SO) increases the risk for severe postoperative complications and worse survival outcomes in patients who have undergone gastrectomy for gastric cancer.

Major finding: SO was associated with an increased risk for serious Clavien-Dindo complications grade >IIIb/IV (odds ratio 2.82; P = .028) and worse overall survival (adjusted hazard ratio 0.45; P = .026) after gastrectomy.

Study details: This single-center retrospective study included 190 patients with gastric cancer who had undergone curative-intent gastrectomy, of which 40 patients had SO.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Juez LD et al. Impact of sarcopenic obesity on long-term cancer outcomes and postoperative complications after gastrectomy for gastric cancer. J Gastrointest Surg. 2022 (Nov 2). Doi: 10.1007/s11605-022-05492-w

Key clinical point: The presence of sarcopenic obesity (SO) increases the risk for severe postoperative complications and worse survival outcomes in patients who have undergone gastrectomy for gastric cancer.

Major finding: SO was associated with an increased risk for serious Clavien-Dindo complications grade >IIIb/IV (odds ratio 2.82; P = .028) and worse overall survival (adjusted hazard ratio 0.45; P = .026) after gastrectomy.

Study details: This single-center retrospective study included 190 patients with gastric cancer who had undergone curative-intent gastrectomy, of which 40 patients had SO.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Juez LD et al. Impact of sarcopenic obesity on long-term cancer outcomes and postoperative complications after gastrectomy for gastric cancer. J Gastrointest Surg. 2022 (Nov 2). Doi: 10.1007/s11605-022-05492-w

Key clinical point: The presence of sarcopenic obesity (SO) increases the risk for severe postoperative complications and worse survival outcomes in patients who have undergone gastrectomy for gastric cancer.

Major finding: SO was associated with an increased risk for serious Clavien-Dindo complications grade >IIIb/IV (odds ratio 2.82; P = .028) and worse overall survival (adjusted hazard ratio 0.45; P = .026) after gastrectomy.

Study details: This single-center retrospective study included 190 patients with gastric cancer who had undergone curative-intent gastrectomy, of which 40 patients had SO.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Juez LD et al. Impact of sarcopenic obesity on long-term cancer outcomes and postoperative complications after gastrectomy for gastric cancer. J Gastrointest Surg. 2022 (Nov 2). Doi: 10.1007/s11605-022-05492-w

Key clinical point: Patients with histological intestinal metaplasia (IM) before eradication of Helicobacter pylori infection, especially at the corpus lesser curvature, may be at an increased risk for gastric cancer after successful eradication.

Major finding: Patients who did vs did not develop gastric cancer had significantly higher histological IM scores at all biopsy sites (P < .05) and a higher proportion of operative link on gastric IM (OLGIM) III/IV stage (P < .01). The corpus lesser curvature had the highest area under the receiver operating characteristic curve value for IM score (0.82), which was similar to OLGIM score (0.82).

Study details: This single-center retrospective study included 247 patients who were diagnosed as positive for H. pylori and achieved infection eradication, of which 11 patients developed gastric cancer after eradication therapy.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Hara D et al. Histopathologically defined intestinal metaplasia in lesser curvature of corpus prior to Helicobacter pylori eradication is a risk factor for gastric cancer development. Helicobacter. 2022;27(6):e12934 (Oct 20). Doi: 10.1111/hel.12934

Key clinical point: Patients with histological intestinal metaplasia (IM) before eradication of Helicobacter pylori infection, especially at the corpus lesser curvature, may be at an increased risk for gastric cancer after successful eradication.

Major finding: Patients who did vs did not develop gastric cancer had significantly higher histological IM scores at all biopsy sites (P < .05) and a higher proportion of operative link on gastric IM (OLGIM) III/IV stage (P < .01). The corpus lesser curvature had the highest area under the receiver operating characteristic curve value for IM score (0.82), which was similar to OLGIM score (0.82).

Study details: This single-center retrospective study included 247 patients who were diagnosed as positive for H. pylori and achieved infection eradication, of which 11 patients developed gastric cancer after eradication therapy.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Hara D et al. Histopathologically defined intestinal metaplasia in lesser curvature of corpus prior to Helicobacter pylori eradication is a risk factor for gastric cancer development. Helicobacter. 2022;27(6):e12934 (Oct 20). Doi: 10.1111/hel.12934

Key clinical point: Patients with histological intestinal metaplasia (IM) before eradication of Helicobacter pylori infection, especially at the corpus lesser curvature, may be at an increased risk for gastric cancer after successful eradication.

Major finding: Patients who did vs did not develop gastric cancer had significantly higher histological IM scores at all biopsy sites (P < .05) and a higher proportion of operative link on gastric IM (OLGIM) III/IV stage (P < .01). The corpus lesser curvature had the highest area under the receiver operating characteristic curve value for IM score (0.82), which was similar to OLGIM score (0.82).

Study details: This single-center retrospective study included 247 patients who were diagnosed as positive for H. pylori and achieved infection eradication, of which 11 patients developed gastric cancer after eradication therapy.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Hara D et al. Histopathologically defined intestinal metaplasia in lesser curvature of corpus prior to Helicobacter pylori eradication is a risk factor for gastric cancer development. Helicobacter. 2022;27(6):e12934 (Oct 20). Doi: 10.1111/hel.12934

Key clinical point: New lesions in different organs and appearance/increase in ascites, but not the originally defined characteristics of hyperprogressive disease (HPD), are disease progression patterns associated with poor prognosis in patients with advanced gastric cancer (AGC) and progressive disease (PD) as the best response to nivolumab therapy.

Major finding: Overall survival was comparable between patients with HPD and those with PD other than HPD (hazard ratio [HR] 1.0; P = 1.0) but significantly shorter in patients who did vs did not develop new lesions in different organs (HR 1.8; P = .0031) and in patients with appearance or increase in ascites vs those with stable or decreased ascites (HR 2.6; P < .0001).

Study details: This multicenter retrospective study included 245 patients with AGC and ≥1 measurable lesion who received nivolumab as a third-line or later treatment.

Disclosures: No source of funding was reported. Some authors declared serving on data safety monitoring or advisory boards or receiving research grants, honoraria, or consulting fees from various sources.

Source: Aoki M et al. Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: A multicenter retrospective study in Japan. Gastric Cancer. 2022 (Nov 1). Doi: 10.1007/s10120-022-01349-y

Key clinical point: New lesions in different organs and appearance/increase in ascites, but not the originally defined characteristics of hyperprogressive disease (HPD), are disease progression patterns associated with poor prognosis in patients with advanced gastric cancer (AGC) and progressive disease (PD) as the best response to nivolumab therapy.

Major finding: Overall survival was comparable between patients with HPD and those with PD other than HPD (hazard ratio [HR] 1.0; P = 1.0) but significantly shorter in patients who did vs did not develop new lesions in different organs (HR 1.8; P = .0031) and in patients with appearance or increase in ascites vs those with stable or decreased ascites (HR 2.6; P < .0001).

Study details: This multicenter retrospective study included 245 patients with AGC and ≥1 measurable lesion who received nivolumab as a third-line or later treatment.

Disclosures: No source of funding was reported. Some authors declared serving on data safety monitoring or advisory boards or receiving research grants, honoraria, or consulting fees from various sources.

Source: Aoki M et al. Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: A multicenter retrospective study in Japan. Gastric Cancer. 2022 (Nov 1). Doi: 10.1007/s10120-022-01349-y

Key clinical point: New lesions in different organs and appearance/increase in ascites, but not the originally defined characteristics of hyperprogressive disease (HPD), are disease progression patterns associated with poor prognosis in patients with advanced gastric cancer (AGC) and progressive disease (PD) as the best response to nivolumab therapy.

Major finding: Overall survival was comparable between patients with HPD and those with PD other than HPD (hazard ratio [HR] 1.0; P = 1.0) but significantly shorter in patients who did vs did not develop new lesions in different organs (HR 1.8; P = .0031) and in patients with appearance or increase in ascites vs those with stable or decreased ascites (HR 2.6; P < .0001).

Study details: This multicenter retrospective study included 245 patients with AGC and ≥1 measurable lesion who received nivolumab as a third-line or later treatment.

Disclosures: No source of funding was reported. Some authors declared serving on data safety monitoring or advisory boards or receiving research grants, honoraria, or consulting fees from various sources.

Source: Aoki M et al. Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: A multicenter retrospective study in Japan. Gastric Cancer. 2022 (Nov 1). Doi: 10.1007/s10120-022-01349-y